Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
125,85 €
-0,59 %
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Robert W. Baird from $157.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $169.00 to $180.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $216.00 to $219.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Guggenheim from $170.00 to $180.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at HC Wainwright from $160.00 to $190.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $173.00 to $181.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Jefferies Financial Group Inc. from $177.00 to $189.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Cantor Fitzgerald from $170.00 to $155.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Barclays PLC from $180.00 to $160.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $160.00 to $165.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at UBS Group AG from $142.00 to $162.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Morgan Stanley from $170.00 to $185.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
BTIG_Research in Workday, Inc. diskutieren